Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023;21(1):75.

Magro CM, Kalomeris T, Roberts A. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal. Ann Diagn Pathol. 2023;63:152101.

Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023;141(8):904-916.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, et al. Novel genetically engineered mouse models for clear cell renal cell carcinoma. Sci Rep. 2023;13(1):8246.

Imada EL, Wilks C, Langmead B, Marchionni L. REPAC: analysis of alternative polyadenylation from RNA-sequencing data. Genome Biol. 2023;24(1):22.

Karaaslan S, Dilcher TL, Abdelsayed M, Goyal A. Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests. J Am Soc Cytopathol. 2023;12(3):189-196.

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023;7(20):6211-6224.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. bioRxiv. 2023.

Boyraz B, Watkins JC, Young RH, Oliva E. Uterine Tumors Resembling Ovarian Sex Cord Tumors: A Clinicopathologic Study of 75 Cases Emphasizing Features Predicting Adverse Outcome and Differential Diagnosis. Am J Surg Pathol. 2023;47(2):234-247.

Stagg J, Golden E, Wennerberg E, Demaria S. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy. Sci Immunol. 2023;8(85):eabq3015.